CIMT 2024：癌症免疫治疗协会第 21 届年会报告。
CIMT 2024: Report on the 21st Annual Meeting of the Association for Cancer Immunotherapy.
机构信息
TRON-Translational Oncology, University Medical Center of Johannes Gutenberg University Mainz gGmbH, Mainz, Germany.
BioNTech SE, Mainz, Germany.
出版信息
Hum Vaccin Immunother. 2024 Dec 31;20(1):2381925. doi: 10.1080/21645515.2024.2381925. Epub 2024 Jul 23.
Abstract
The 21 Association for Cancer Immunotherapy (CIMT) Annual Meeting took place from May 15 to May 17 in Mainz, Germany, and was attended by a total of 855 academic and clinical professionals hailing from 33 different countries. The conference served as a platform for these experts to convene and discuss the latest breakthroughs in cancer immunology and immunotherapy research. Dedicated sessions covering advancements in artificial intelligence tools for cancer immunotherapy research, as well as the landscape of cancer care and cancer immunotherapy trials on the African continent, prompted lively and informative discussions among the attendees. This report aims to provide an overview of the most noteworthy highlights and key takeaways from CIMT2024.
摘要
第 21 届癌症免疫治疗协会（CIMT）年会于 5 月 15 日至 17 日在德国美因茨举行，共有来自 33 个不同国家的 855 名学术和临床专业人士参加。本次会议为这些专家提供了一个平台，他们聚集在这里讨论癌症免疫学和免疫治疗研究的最新突破。专门的会议涵盖了癌症免疫治疗研究中人工智能工具的进展，以及非洲大陆癌症治疗和癌症免疫治疗试验的现状，这引发了与会者的热烈而富有信息量的讨论。本报告旨在概述 CIMT2024 年会上最值得关注的要点和重要收获。
相似文献
1
CIMT 2024: Report on the 21st Annual Meeting of the Association for Cancer Immunotherapy.CIMT 2024：癌症免疫治疗协会第 21 届年会报告。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2381925. doi: 10.1080/21645515.2024.2381925. Epub 2024 Jul 23.
2
CIMT 2018: Pushing frontiers in cancer immunotherapy - Report on the 16 Annual Meeting of the Association for Cancer Immunotherapy.CIMT 2018：推动癌症免疫治疗的前沿进展——第十六届癌症免疫治疗协会年会报告。
Hum Vaccin Immunother. 2018;14(12):2864-2873. doi: 10.1080/21645515.2018.1504526. Epub 2018 Aug 29.
3
CIMT 2021: report on the 18th Annual Meeting of the Association for Cancer Immunotherapy.CIMT 2021：癌症免疫治疗协会第十八届年会报告。
Hum Vaccin Immunother. 2022 Dec 31;18(1):2024416. doi: 10.1080/21645515.2021.2024416. Epub 2022 Feb 7.
4
CIMT 2016: Mechanisms of efficacy in cancer immunotherapy - Report on the 14th Annual Meeting of the Association for Cancer Immunotherapy May 10-12 2016, Mainz, Germany.2016年癌症免疫治疗国际会议：癌症免疫治疗疗效机制——2016年5月10 - 12日于德国美因茨举行的癌症免疫治疗协会第14届年会报告
Hum Vaccin Immunother. 2016 Nov;12(11):2805-2812. doi: 10.1080/21645515.2016.1206677. Epub 2016 Jul 19.
5
CIMT 2022: Report on the 19th Annual Meeting of the Association for Cancer Immunotherapy.CIMT 2022：癌症免疫治疗协会第十九届年会报告。
Hum Vaccin Immunother. 2022 Nov 30;18(6):2124785. doi: 10.1080/21645515.2022.2124785. Epub 2022 Oct 12.
6
CIMT 2023: report on the 20th Annual Meeting of the Association for Cancer Immunotherapy.2023年国际肿瘤免疫治疗大会：癌症免疫治疗协会第20届年会报告
Immunooncol Technol. 2023 Sep 12;20:100397. doi: 10.1016/j.iotech.2023.100397. eCollection 2023 Dec.
7
CIMT 2013: advancing targeted therapies--report on the 11th Annual Meeting of the Association for Cancer Immunotherapy, May 14-16 2013, Mainz, Germany.2013年癌症免疫治疗学会年会：推进靶向治疗——2013年5月14 - 16日于德国美因茨召开的第11届癌症免疫治疗学会年会报告
Hum Vaccin Immunother. 2013 Sep;9(9):2025-32. doi: 10.4161/hv.25768. Epub 2013 Jul 22.
8
Mechanisms of efficacy in cancer immunotherapy: 14th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Mainz, Germany, May 10-12, 2016.癌症免疫治疗的疗效机制：2016年5月10 - 12日于德国美因茨举行的第14届癌症免疫治疗协会年会（CIMT）
Cancer Immunol Immunother. 2017 May;66(5):673-681. doi: 10.1007/s00262-017-1974-2. Epub 2017 Mar 1.
9
CIMT 2014: Next waves in cancer immunotherapy--report on the 12th annual meeting of the Association for Cancer Immunotherapy: May 6–8 2014, Mainz, Germany.2014年癌症免疫治疗进展：癌症免疫治疗协会第12届年会报告——2014年5月6 - 8日于德国美因茨召开
Hum Vaccin Immunother. 2014;10(10):3090-100. doi: 10.4161/hv.29767.
10
Cancer immunotherapy achieves breakthrough status: 12th annual meeting of the association for cancer immunotherapy (CIMT), Mainz, Germany, May 6-8, 2014.癌症免疫疗法取得突破性进展：2014年5月6日至8日于德国美因茨召开的癌症免疫疗法协会（CIMT）第12届年会。
Cancer Immunol Immunother. 2015 Jul;64(7):923-30. doi: 10.1007/s00262-014-1643-7. Epub 2014 Dec 30.
引用本文的文献
1
Analysis of a pan-cancer panel reveals the amino acid metabolism-related gene MTHFD1 as a potential prognostic and immunotherapeutic biomarker.一项泛癌研究分析显示，氨基酸代谢相关基因MTHFD1是一种潜在的预后和免疫治疗生物标志物。
Exp Ther Med. 2025 May 20;30(1):142. doi: 10.3892/etm.2025.12892. eCollection 2025 Jul.
本文引用的文献
1
Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer.局部晚期错配修复缺陷型结直肠癌的新辅助免疫治疗。
N Engl J Med. 2024 Jun 6;390(21):1949-1958. doi: 10.1056/NEJMoa2400634.
2
Discovery of tumor-reactive T cell receptors by massively parallel library synthesis and screening.通过大规模平行文库合成和筛选发现肿瘤反应性T细胞受体。
Nat Biotechnol. 2025 Feb;43(2):214-222. doi: 10.1038/s41587-024-02210-6. Epub 2024 Apr 23.
3
Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers.嵌合抗原受体 T 细胞的临床前开发，该细胞具有抗原诱导的 IL18 执行功能，用于治疗 GD2 阳性实体瘤。
Clin Cancer Res. 2024 Aug 15;30(16):3564-3577. doi: 10.1158/1078-0432.CCR-23-3157.
4
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.2022 年全球癌症统计数据：全球 185 个国家和地区 36 种癌症的发病率和死亡率全球估计数。
CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4.
5
Cancer cell genetics shaping of the tumor microenvironment reveals myeloid cell-centric exploitable vulnerabilities in hepatocellular carcinoma.肿瘤微环境中的癌细胞遗传学塑造揭示了肝癌中以髓样细胞为中心的可利用脆弱性。
Nat Commun. 2024 Mar 22;15(1):2581. doi: 10.1038/s41467-024-46835-2.
6
A functional identification platform reveals frequent, spontaneous neoantigen-specific T cell responses in patients with cancer.功能鉴定平台揭示癌症患者中频繁、自发的新抗原特异性 T 细胞反应。
Sci Transl Med. 2024 Feb 28;16(736):eabj9905. doi: 10.1126/scitranslmed.abj9905.
7
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19 B cell tumors: a phase 1/2 trial.同种异体 CD19 特异性 CAR-NK 细胞治疗 CD19 B 细胞肿瘤的安全性、有效性和反应决定因素：一项 1/2 期试验。
Nat Med. 2024 Mar;30(3):772-784. doi: 10.1038/s41591-023-02785-8. Epub 2024 Jan 18.
8
Trans-vaccenic acid reprograms CD8 T cells and anti-tumour immunity.反式- Vaccenic 酸重编程 CD8 T 细胞和抗肿瘤免疫。
Nature. 2023 Nov;623(7989):1034-1043. doi: 10.1038/s41586-023-06749-3. Epub 2023 Nov 22.
9
Probiotic-guided CAR-T cells for solid tumor targeting.益生菌引导的 CAR-T 细胞用于实体瘤靶向治疗。
Science. 2023 Oct 13;382(6667):211-218. doi: 10.1126/science.add7034. Epub 2023 Oct 12.
10
Linked CD4+/CD8+ T cell neoantigen vaccination overcomes immune checkpoint blockade resistance and enables tumor regression.CD4+/CD8+ T 细胞新抗原疫苗接种克服免疫检查点阻断耐药性并使肿瘤消退。
J Clin Invest. 2023 Sep 1;133(17):e164258. doi: 10.1172/JCI164258.
Zotero 插件